Identification method for O-glycosylation site of insulin and analogues thereof
A technology of glycosylation site and identification method, applied in the field of identification of insulin and its analogs O-glycosylation site, can solve the problems of high cost, high price, low purchase amount and the like, and achieves strong practicability, High accuracy and simple operation effect
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0085] Example 1 Elastase Enzyme Reducing Peptide Map Enzyme Cutting Treatment Time Investigation
[0086] Elastase is a serine-like protease that preferentially cleaves the C-terminus of alanine, valine, serine, glycine, leucine, or isoleucine. Peptide EQCCTS (A3-A9) can theoretically be obtained by cleavage of recombinant human insulin with elastase, but the theoretical peptide EQCCTS has not been obtained through preliminary experimental results, which may be due to valine, leucine, isoleucine Dipeptide derivatives of acid and alanine are potent competitive inhibitors of Elastase.
[0087] It has been reported in the literature that Elastase has multiple active centers and can cut many sites, but it only preferentially cuts the C-terminus of alanine, valine, serine, glycine, leucine or isoleucine and Elastase has the ability to degrade elastin activity, as well as the activity of hydrolyzing protein.
[0088] In order to obtain key fragment ion peaks for subsequent mass s...
Embodiment 2
[0096] Example 2 Q-TOF-MS / MS CID Fragmentation Energy Optimization
[0097] MS / MS analysis was performed on the key glycosylated peptides in the glycosylated impurity Elastase digestion and reduction peptide map, and the peptide with m / z688.2518 (CTSIC glycosylation) was used as the parent ion, and the CID of the peptide was Fragmentation energy has been optimized. During the experiment, it was found that when performing MS / MS analysis, when the energy is too low, the desired target fragments cannot be obtained, and when the energy is too high, the sugar is easily broken during the process of CID fragmentation, and the target cannot be obtained fragment ions.
[0098] Chromatographic conditions: Column information: Welch C18, 4.6mm×250mm, 5μm (No.: 20121108); Injection volume: 20μl; Wavelength: 214nm; Column temperature: 40°C; Flow rate: 1.0ml / min; Flow into the mass spectrometer; 0~4min: to waste; 4~50min: to MS; post-run time: 12min; gradient elution: elution time 0~50min,...
Embodiment 3
[0103] Example 3 Confirmation of glycosylation sites of recombinant insulin glargine glycosylation impurities
[0104] The glycosylation impurities (6225Da) in the crude drug of recombinant insulin glargine (molecular weight 6063Da) were confirmed by Elastase enzymatic hydrolysis.
[0105] By comparing the Elastase enzymatic profile of insulin glargine glycosylation impurities and insulin glargine standard after reduction, in the TIC profile of glycosylation impurities, it is found that the abundance of glycosylated peptides at m / z 688.2532 is higher, which may be CTSIC or CCTSI glycosylated peptides, but the corresponding glycosylated peptide peaks were not found in the spectrum of the glargine standard. In order to determine the glycosylation site, the glycosylated peptide was subjected to Target MS / MS analysis showed that m / z688.2532 was identified by Target MS / MS as a CTSIC glycosylated peptide and the glycosylation site was on threonine at position A8.
PUM
| Property | Measurement | Unit |
|---|---|---|
| wavelength | aaaaa | aaaaa |
| molecular weight | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More 


